



HAL
open science

Initiating Evaluation of Composite Outcome Measures for Psoriatic Arthritis: 2022 Updates From the GRAPPA-OMERACT Working Group

Ying-Ying Leung, William Tillett, Maarten de Wit, Ana-Maria Orbai, Laura Coates, Oliver Fitzgerald, Philip Helliwell, Vibeke Strand, Philip Mease, Niti Goel, et al.

► To cite this version:

Ying-Ying Leung, William Tillett, Maarten de Wit, Ana-Maria Orbai, Laura Coates, et al.. Initiating Evaluation of Composite Outcome Measures for Psoriatic Arthritis: 2022 Updates From the GRAPPA-OMERACT Working Group. *Journal of Rheumatology*, 2023, 50 (Suppl 2), pp.53-57. 10.3899/jrheum.2023-0530 . hal-04306132

HAL Id: hal-04306132

<https://hal.sorbonne-universite.fr/hal-04306132v1>

Submitted on 24 Nov 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Running Title: Composite outcome measures for PsA

Initiating evaluation of composite outcome measures for psoriatic arthritis: 2022 updates from the GRAPPA-OMERACT Working Group

Ying-Ying Leung, William Tillett, Maarten de Wit, Ana-Maria Orbai, Laura C Coates, Oliver FitzGerald, Philip S Helliwell, Vibeke Strand, Philip Mease, Niti Goel, Robin Christensen, Joseph F. Merola, Christine Lindsay, Alexis Ogdie, Laure Gossec, Dafna D Gladman

Source of Support: **YYL** is funded by the Clinician Scientist award of the National Medical Research Council, Singapore (NMRC/CSA-INV/0022/2017). The views expressed are those of the author(s) and not necessarily those of the NMRC. **AMO** is funded by the Jerome L. Greene Foundation Scholar Award, the Staurulakis Family Discovery Award, the Rheumatology Research Foundation, and the National Institutes of Health (NIH) through the Rheumatic Diseases Resource-based Core Center (P30-AR053503, Cores A and D; and P30-AR070254, Cores A and B). All statements in this report, including its findings and conclusions, are solely those of the authors and do not necessarily represent the views of the NIH, the National Institute of Arthritis Musculoskeletal and Skin Diseases (NIAMS), or the Rheumatology Research Foundation (RRF). **AO** is funded by the Rheumatology Research Foundation and NIH/NIAMS K23 AR063764 and R01 AR072363. **RC** (i.e., the Parker Institute) is supported by a core grant from the Oak Foundation (OCAY-18-774-OFIL). **JFM** is funded by the National Psoriasis Foundation Psoriatic Disease Research Fellowship. **LCC** is funded by a NIHR Research Clinician Scientist award. The research was supported by the National Institute of Health Research (NIHR) Oxford Biomedical Research Centre (BRC). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health.

Author Information:

YY Leung, MB ChB, MD, [ORCID: [0000-0001-8492-6342](https://orcid.org/0000-0001-8492-6342)], Associate Professor, Duke-NUS Medical School, Singapore, Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, katyccc@hotmail.com;

W Tillett, BSc, MB ChB, PhD, MRCP, [ORCID: [0000-0001-7531-4125](https://orcid.org/0000-0001-7531-4125)], Consultant Rheumatologist, Senior Lecturer, Royal National Hospital for Rheumatic Diseases, University of Bath, Bath, United Kingdom, w.tillett@nhs.net;

M de Wit, PhD, [ORCID: [0000-0001-5948-0000](https://orcid.org/0000-0001-5948-0000)], GRAPPA Patient Research Partner, Amsterdam, The Netherlands, martinusdewit@hotmail.com;

A-M Orbai, MD, MHS, [ORCID: [0000-0001-8644-8567](https://orcid.org/0000-0001-8644-8567)], Associate Professor of Medicine, Director Psoriatic Arthritis Program, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA, aorbai1@jhmi.edu;

LC Coates, MB ChB, PhD, [ORCID: [0000-0002-4756-663X](https://orcid.org/0000-0002-4756-663X)], Associate Professor, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, laura.coates@ndorms.ox.ac.uk;

O FitzGerald, MD, FRCPI, FRCP(UK), [ORCID: [0000-0002-6607-6070](https://orcid.org/0000-0002-6607-6070)], Consultant Rheumatologist and Newman Clinical Research Professor, Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland, oliver.fitzgerald@ucd.ie;

PS Helliwell, MD [ORCID: [0000-0002-4155-9105](https://orcid.org/0000-0002-4155-9105)], Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, LS7 4SA. Email: p.helliwell@leeds.ac.uk;

V Strand, MD, [ORCID: [0000-0003-4978-4072](https://orcid.org/0000-0003-4978-4072)], Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California, USA, vstrand@stanford.edu;

PJ Mease, MD, [ORCID: [0000-0002-6620-0457](https://orcid.org/0000-0002-6620-0457)], Rheumatology Research, Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, Washington, USA, pmease@philipmease.com;

N Goel, MD, [ORCID: [0000-0001-5869-5157](https://orcid.org/0000-0001-5869-5157)], GRAPPA Patient Research Partner; Senior Vice President, Therapeutic Area Head of Rheumatology, TrialSpark; Adjunct Assistant Professor, Duke University School of Medicine, Durham, North Carolina, USA, agwngw1@gmail.com;

R Christensen, BSc, MSc, PhD; [ORCID: [0000-0002-6600-0631](https://orcid.org/0000-0002-6600-0631)], Section for Biostatistics and Evidence-Based Research; The Parker Institute, Bispebjerg and Frederiksberg Hospital, University of Copenhagen, Copenhagen, Denmark; and Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Odense University Hospital, Denmark. Robin.Christensen@regionh.dk;

JF Merola, MD MMSc [ORCID: [0000-0001-6514-4353](https://orcid.org/0000-0001-6514-4353)], Harvard Medical School, Brigham and Women's Hospital; Boston, MA, USA, jfmerola@bwh.harvard.edu;

CA Lindsay, PharmD, [ORCID 0000-0001-6141-2824], GRAPPA Patient Research Partner, Prosper, Texas, USA, employed by Arcutis Biotherapeutics, Inc. calindsay1@gmail.com;

A Ogdie, MD, MSCE, [ORCID: 0000-0002-4639-0775], Associate Professor of Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA, alogdie@pennmedicine.upenn.edu;

Laure Gossec, MD, PhD, [ORCID: 0000-0002-4528-310X], Professor of rheumatology, (1) Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris France; (2) AP-HP, Pitié-Salpêtrière hospital, Rheumatology department, Paris, France, laure.gossec@aphp.fr;

DD Gladman, MD, FRCPC, [ORCID: 0000-0002-9074-0592], Professor of Medicine, University of Toronto, Senior Scientist, Schroeder Arthritis Institute, Krembil Research Institute, Director, Psoriatic Arthritis Program, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada, dafna.gladman@utoronto.ca.

Corresponding Author: Ying Ying Leung, MB ChB, MD, Associate Professor, Department of Rheumatology and Immunology, Singapore General Hospital, 20 College Road, the Academia, Singapore S169856; phone 65 63265276; fax 65 62203321; email katyccc@hotmail.com

Key Indexing Terms: Psoriatic arthritis, outcome measures, physical function, composite outcome measures

Conflict of interest:

YYL has received speaker fee from AbbVie, DKSH, Janssen, Novartis, and Pfizer. **WRT** has received research grants, speaker or consulting fees from Abbvie, Amgen, Eli Lilly, GSK, Janssen, MSD, Novartis, Pfizer and UCB. **MDW:** Over the last three years Stichting Tools has received fees for lectures or consultancy provided by **MDW** from Celgene, Eli Lilly, Pfizer and UCB. **NG** is a stockholder in UCB and Abcuro. **JFM** is a consultant and/or investigator for Amgen, Arcutis, Bristol-Myers Squibb, Abbvie, Dermavant, Eli Lilly, Novartis, Janssen, UCB, Sanofi, Regeneron, Sun Pharma, Biogen, Pfizer, and Leo Pharma. **LG** has received research grants from Sandoz, UCB; consulting fees from AbbVie, Amgen, BMS, Celltrion, Galapagos, Janssen, Lilly, MSD, Novartis, Pfizer, Sandoz, UCB. **DG** has received research grants from Abbvie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer and UCB; consulting fees from Abbvie, Amgen, BMS, Gilead, Eli Lilly, Janssen, Novartis, Pfizer and UCB. All other authors declare no relevant conflicts of interest.

ABSTRACT

The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)-Outcome Measures in Rheumatology (OMERACT) Psoriatic Arthritis (PsA) working group (including rheumatologists, dermatologists, methodologists, and patient research partners) provided updates at the 2022 GRAPPA annual meeting on its work to evaluate composite outcome measures for PsA. Ten composite outcome measures were considered. Initial steps were to define the population, the purpose of use, and the proposed pros and cons of the ten candidate composites instruments for PsA. Preliminary Delphi exercises within the working group and GRAPPA stakeholders confirmed a high priority for evaluating Minimal Disease Activity (MDA), moderate priority for Disease Activity in PsA (DAPSA), ACR response criteria, Psoriatic Arthritis Disease Activity Score (PASDAS), Composite Psoriatic Disease Activity Index (CPDAI), 3 Visual analogue scale (VAS) and 4 VAS; and low priority for Disease Activity Score-28 (DAS28), Psoriatic Arthritis Responder Criteria (PsARC), and Routine Assessment of Patient Index Data 3 (RAPID 3). Further appraisal of candidate composite instruments is ongoing.

Introduction

Following the update of the core domain set for psoriatic arthritis (PsA) in 2016 ¹, the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) - Outcome Measures in Rheumatology (OMERACT) working group has been developing an outcome measurement set for important domains for clinical trials of psoriatic arthritis (PsA) ¹. Over the years, several instruments have been fully/ provisionally endorsed for some of the core domains (Table 1). This group aims to evaluate candidate composite outcome measures for PsA. This report summarizes the current plans to prioritise further evaluation of these composite outcome measures under the OMERACT filter 2.2 framework ².

Why do we need composite outcome measures for PsA?

Composite outcome measures allow the combination of outcomes measuring several domains of similar significance to clinicians and patients to generate a single score to give an estimate net clinical benefit of an

intervention. Typically, the US Food and Drug Administration (FDA) defines “composite event endpoints” as the occurrence of any of the events³. On the contrary, composite outcome measures have been commonly used for measuring the concept of disease activity in rheumatology, and recognised by the European Medicines Agency (EMA) guideline⁴. The potential benefits of using composite outcome measures include the potential to reduce the sample size, duration of follow-up in clinical trials, thus avoiding statistical adjustment for multiple testing. Composite outcome measures also reduce the risk of underestimating disease through the measurement of multiple domains as they incorporate patient and clinician perspectives and enhance face validity of the outcome measure⁵.

Recently, OMERACT has set forth a 4-step framework for the evaluation of composite outcome measures⁵, including choosing the domains to be combined, selecting high quality instruments for the domains, weighing the domains in the composite, and finally putting the composite outcome measures through the OMERACT filter 2.2 to comprehensively appraise an outcome measure’s validity of Truth, Discrimination, and Feasibility². Composite outcome measures were further subclassified by the OMERACT filter 2.2 into composite outcome domain (COD) and multi-outcome domain (MOD) measures which can be conceptualized as categorical and continuous composite outcome measures respectively.

Several existing composite outcome measures have been used in PsA clinical trials and longitudinal studies, yet consensus on which measure to use in different settings has not been reached^{6,7}. Although there are emerging data supporting their psychometric properties⁸⁻¹¹, none of the composite outcome measures have undergone comprehensive evaluation using the OMERACT filter. As OMERACT initiates new methodology guidance on evaluation of composites^{2,5}, the use of composite outcome measures in PsA is being revisited.

The composite outcome measures working group

A working group of 16 persons, including 11 rheumatologists, 1 dermatologist, 3 patient research partners (PRP), and 1 methodologist was set up. The goal of the project is to develop recommendations on composite outcome measures for PsA to be used in clinical trials and longitudinal studies. The working group opted to evaluate existing composite outcome measures rather than developing a new instrument. The group may consider the latter if none fulfils the measurement requirements. To succeed, each of the candidate composite outcome measures should be evaluated in a specified population, for use in a well-defined context with intended purpose of use². There could be different composite outcome measures appropriate for different settings.

The candidate composite outcome measures.

The working group selected ten candidate composite outcome measures and carefully defined the population and context of use (Table 2 and Supplement). Notably, none of the existing composite outcome measures encompass all components of the core domain set (Table 3). Some examples of composite outcome measures stratified according to domains, scoring, and weighting were illustrated during the GRAPPA annual congress. The working group acknowledged the Psoriatic Arthritis Impact of Disease (PsAID)¹² as a composite outcome that measures the impact of PsA on multiple aspects of patients' lives. As the PsAID12 has been endorsed by both GRAPPA and OMERACT as a measure of the health-related quality of life (HRQoL) domain¹³, the working group decided not to include the PsAID in the present project.

The working group then conducted a preliminary Delphi exercise¹⁴ in June 2022. For each composite outcome measure, participants rated 1) the agreement on the defined purpose of further evaluation and the 2) priority to be evaluated using the OMERACT filter on a scale of 1 to 9 with 1-3 not important, 4-6 important but not critical, and 7-9 critically important. A similar, but more succinct Delphi exercise for a broader GRAPPA stakeholder was conducted subsequently. Overall, 149 members responded (77.4% rheumatologists, 15.1% dermatologists, 2.7% PRPs, and 4.8% others). In the working group Delphi, the ACR response criteria¹⁵, Minimal Disease Activity (MDA)¹⁶, and Disease Activity in PsA (DAPSA)¹⁷ received consensus rating as critically important to move forward; Psoriatic Arthritis Disease Activity Score (PASDAS)¹⁸, Composite Psoriatic Disease Activity Index (CPDAI)¹⁹, and 3/ 4 Visual analogue scale (VAS)²⁰ were important but not critical; Disease Activity Score-28 (DAS28)²¹, Psoriatic Arthritis Responder Criteria (PsARC)²², and Routine Assessment of Patient Index Data 3 (RAPID 3)²³ were rated low priority/not important to proceed with further evaluation. In contrast, in the Delphi exercise for GRAPPA stakeholders, only MDA received consensus rating as critically important (Table 2).

Patient perspective

It is important for patients to have a composite outcome measure that provides a reliable indicator of how they are doing. However, no existing composite outcome measure accounts for all domains in the core domain set that both patients and clinicians recognized as essential to include in all PsA clinical trials¹. There are some additional points that would be important from the patient perspective. First, the composite outcome measures should be comprehensive, measuring as many domains as possible that are important to patients. Secondly, the measures should be disease specific. There are numerous composite outcome measures developed for other conditions that are still utilized in clinical trials for PsA and may not represent a match to the domains relevant to PsA patients. Although a change towards using PsA-specific composite outcome measures may not be immediate, the conversation towards such a change should be continued. Thirdly, composite outcome measures developed with patient participation should be encouraged. Some of the important domains to include were fatigue and skin disease activity.

In the question-and-answer session during the annual GRAPPA meeting in July 2022, PRPs once again echoed the importance of the comprehensiveness of composite outcome measures. At the same time, patients may experience flares in some domains, while other domains are getting better. Therefore, it may be useful to evaluate the changes in different domains in response to treatment to help select the best domains to be combined in the composite outcome measures. This is especially important for composite outcome measures used as responder criteria in trials.

Conclusion

The composite outcome measure working group has set the stage to re-evaluate the use of composite outcome measures in PsA. Preliminary Delphi exercise indicated a high priority for evaluating MDA among GRAPPA stakeholders; moderate priority for DAPSA, ACR responder criteria, PASDAS, CPDAI, and 3 / 4VAS. Further evidence-based evaluation of composite outcome measures will follow to enable consensus in the selection of relevant composite outcome measures for use in PsA clinical trials.

Table 1. Update on the overall project for Core Measurement Set for PsA

Core Domains	Core Instruments/ Work progress	Team Lead
MSK disease activity		
- Peripheral joints*	Fully endorsed: 66/68 Swollen/Tender joint count	YYL
- Enthesitis*	Work on clinical enthesitis in progress SLR on US enthesitis completed, development of new instrument required and in progress	AO LE
- Dactylitis*	Work in progress	
- Axial	Awaiting formal definition of Axial involvement	
Skin	-	
Pain	-	
Patient Global Assessment	-	
Physical Function*	Provisionally endorsed: HAQ-DI, SF-36 PF	YYL
HRQoL*	Provisionally endorsed: PsAID	AMO
Fatigue*	Work in progress	AMO
Systemic inflammation	SLR completed, more data needed	LE
Structural Damage**	SLR completed, more data needed	WT

*Prioritized domains.

‡ This is not in the inner circle of core domain set but required at least once in the development program of intervention.

Abbreviations. HAQ-DI: Health Assessment Questionnaire-Disability Index; HRQoL: health-related quality of life; PsA: psoriatic arthritis; PsAID: Psoriatic Arthritis Impact of Disease; SF-36 PF: Medical Outcome Short Form 36- Physical Functioning domain; SLR: systematic literature review.

Team leaders: AO: Alexis Ogdie, AMO: Ana-Maria Orbai, LE: Lihi Eder; WT: William Tillett; YYL: Ying Ying Leung.

Table 2. Defined purpose of use of candidate composite measures and results of Delphi exercises from working group and GRAPPA stakeholders

Candidate composite measures	Defined population	Purpose of Use	Working group votes [‡] (n=13)		GRAPPA stakeholder votes [‡] (n=149)
			Agreement* ≥7, (%)	Priority* ≥7, (%)	Priority* ≥7, (%)
ACR20/50/70	PsA patients with active disease	Use in RCTs, as a primary efficacy responder index for peripheral arthritis	92.3	76.9	60.4
PsARC	PsA patients with active disease	Use in RCTs, as an efficacy outcome responder index for peripheral arthritis	38.5	15.4	NA [§]
MDA/ VLDA	PsA patients with active disease	Use in RCTs, as a responder index for psoriatic disease to assess low disease activity/ remission In LOS, as a treatment target in clinical management	100	100	87.9
DAS28	PsA patients with active disease	Use in RCTs/ LOS, as a measure of disease activity in peripheral arthritis Cut-offs can be used as responder index in RCTs or treatment targets in LOS	7.7	0	NA [§]
CPDAI	PsA patients with active disease	Use in RCTs or LOS, as a measurement of disease activity	50	33.3	42.3
DAPSA/ cDAPSA	PsA patients with active peripheral arthritis	Use in RCTs or LOS, as a measurement of peripheral arthritis disease activity Cut-offs can be used as responder criteria in RCTs or treatment targets in LOS	76.9	83.3	68.5
PASDAS	PsA patients with active disease	Use in RCTs/ LOS, as a measurement of psoriatic disease activity Cut-offs can be used as responder index in RCTs or treatment targets in LOS	76.9)	69.2)	57.1
3VAS	PsA patients	Use in LOS/clinical practice, as a measurement of psoriatic disease activity	61.5 ^P	53.8 ^P	45.0
4VAS					49.7

RAPID3	PsA patients	Use in RCTs/LOS/clinical practice, as a measurement of psoriatic disease activity	30.8	23.1	NA [§]
---------------	--------------	--------------------------------------------------------------------------------------	------	------	-----------------

[¥] Rated on scale 1-9: (1-3 not important) (4-6 important, but not critical) (7-9 critically important).

^{*} ≥70% of participants rating 7 and above would be considered agreement.

^P 3VAS/4VAS were voted together in working group Delphi.

[§] These composite outcome measures were excluded in the Delphi exercise for GRAPPA stakeholder.

Abbreviations. ACR20/50/70: American College of Rheumatology 20/50/70% reduction; MDA: Minimal Disease Activity; CPDAI: Composite Psoriatic Disease Activity Index; DAPSA: Disease Activity Index for Psoriatic Arthritis; cDAPSA: clinical DAPSA; LOS: longitudinal observational studies; PsA: psoriatic arthritis; PASDAS: Psoriatic Arthritis Disease Activity Score; RCT: randomized controlled trial; VAS: Visual Analogue Scale; VLDA: Very Low Disease Activity.

Table 3. Mapping candidate composite measures to core domains for PsA

		Core Domains for PsA										
		MSK disease activity				Skin	Pain	PGA	HRQoL	Fatigue	Physical Function	Systemic Inflammation
		Arthritis	Enthesitis	Dactylitis	Axial							
(COD)	PASDAS	✓	✓	✓				✓			✓	✓
	DAPSA/cDAPSA	✓					✓	✓				✓
	DAS28	✓						✓				✓
	3 VAS					✓		✓				
	4 VAS	✓				✓	✓					
	RAPID 3						✓	✓			✓	
	CPDAI	✓	✓	✓	✓	✓			✓		✓	
(MOD)	ACR20/50/70	✓					✓	✓			✓	✓
	MDA/VLDA	✓	✓			✓	✓	✓			✓	

Abbreviations. ACR20/50/70: American College of Rheumatology 20/50/70% reduction; COD: composite outcome domain; CPDAI: Composite Psoriatic Disease Activity Index; DAS28: Disease Activity Score-28 joints for rheumatoid arthritis; DAPSA: Disease Activity Index for Psoriatic Arthritis; cDAPSA: clinical DAPSA; HRQoL: health-related quality of life; LOS: longitudinal observational studies; MDA: Minimal Disease Activity; MOD: multi-outcome domain; MSK: musculoskeletal; PsA: psoriatic arthritis; PASDAS: Psoriatic Arthritis Disease Activity Score; PGA: patient global assessment; RCT: randomized controlled trial; RAPID 3: Routine Assessment of Patient Index Data 3; VAS: Visual Analogue Scale; VLDA: Very Low Disease Activity.

REFERENCES

1. Orbai AM, de Wit M, Mease P, et al. International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials. *Ann Rheum Dis* 2017;76:673-80.
2. Maxwell LJ, Beaton DE, Boers M, et al. The evolution of instrument selection for inclusion in core outcome sets at OMERACT: Filter 2.2. *Semin Arthritis Rheum* 2021;51:1320-30.
3. Department of Health and Human Services FaDA. Multiple Endpoints in Clinical Trials. Guidance for industry, draft guidance. U.S. [Internet. Accessed 20 Jan 2023, Available from: <https://www.fda.gov/files/drugs/published/Multiple-Endpoints-in-Clinical-Trials-Guidance-for-Industry.pdf>.
4. Guideline on clinical investigation of medicinal products for the treatment of rheumatoid arthritis. [Internet. Accessed 20 Jan 2023, Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-rheumatoid-arthritis_en.pdf.
5. Wells GA, Tugwell P, Tomasson G, et al. Composite outcomes at OMERACT: Multi-outcome domains and composite outcome domains. *Semin Arthritis Rheum* 2021;51:1370-7.
6. Coates LC, Mumtaz A, Helliwell PS, et al. Development of a disease severity and responder index for psoriatic arthritis (PsA)--report of the OMERACT 10 PsA special interest group. *J Rheumatol* 2011;38:1496-501.
7. Smolen JS, Schöls M, Braun J, et al. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. *Ann Rheum Dis* 2018;77:3-17.
8. Coates LC, Smolen JS, Mease PJ, et al. Comparative performance of composite measures from two phase III clinical trials of ixekizumab in psoriatic arthritis. *RMD Open* 2022;8.
9. Schneeberger EE, Citera G, Nash P, et al. Comparison of disease activity index for psoriatic arthritis (DAPSA) and minimal disease activity (MDA) targets for patients with psoriatic arthritis: A post hoc analysis of data from phase 3 tofacitinib studies. *Semin Arthritis Rheum* 2023;58:1521-34.
10. Helliwell PS, Mease PJ, Kavanaugh A, et al. Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trial. *RMD Open* 2022;8.
11. Coates LC, Ritchlin CT, Gossec L, et al. Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis. *Rheumatology (Oxford)* 2023;62:606-16.
12. Gossec L, de Wit M, Kiltz U, et al. A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative. *Ann Rheum Dis* 2014;73:1012-9.
13. Orbai A-M, Holland R, Leung YY, et al. PsAID12 Provisionally Endorsed at OMERACT 2018 as Core Outcome Measure to Assess Psoriatic Arthritis-specific Health-related Quality of Life in Clinical Trials. *The Journal of Rheumatology* 2019;46:990-5.
14. Nasa P, Jain R, Juneja D. Delphi methodology in healthcare research: How to decide its appropriateness. *World J Methodol* 2021;11:116-29.
15. Felson D, Criteria ACoRcTRI. A proposed revision to the ACR20: The hybrid measure of American College of Rheumatology response. *Arthritis Care & Research* 2007;57:193-202.
16. Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. *Annals of the rheumatic diseases* 2010;69:48-53.
17. Schoels M, Aletaha D, Funovits J, Kavanaugh A, Baker D, Smolen JS. Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis. *Ann Rheum Dis* 2010;69:1441-7.
18. Helliwell PS, FitzGerald O, Fransen J, et al. The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). *Ann Rheum Dis* 2013;72:986-91.
19. Mumtaz A, Gallagher P, Kirby B, et al. Development of a preliminary composite disease activity index in psoriatic arthritis. *Ann Rheum Dis* 2011;70:272-7.

20. Tillett W, FitzGerald O, Coates LC, et al. Composite Measures for Clinical Trials in Psoriatic Arthritis: Testing Pain and Fatigue Modifications in a UK Multicenter Study. *J Rheumatol Suppl* 2021;97:39-44.
21. van der Heijde DM, van 't Hof MA, van Riel PL, et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. *Ann Rheum Dis* 1990;49:916-20.
22. Clegg DO, Reda DJ, Mejias E, et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. *Arthritis Rheum* 1996;39:2013-20.
23. Pincus T, Yazici Y, Bergman MJ. RAPID3, an index to assess and monitor patients with rheumatoid arthritis, without formal joint counts: similar results to DAS28 and CDAI in clinical trials and clinical care. *Rheumatic Disease Clinics* 2009;35:773-8.